TVGN TEVOGEN BIO HOLDINGS INC

Dr. Ryan Saadi Commends Individuals Who Dedicate Time to Public Service, and Congratulates Mayor Victor Sordillo on His Induction Into the NJ League of Municipalities Hall of Fame

Dr. Ryan Saadi Commends Individuals Who Dedicate Time to Public Service, and Congratulates Mayor Victor Sordillo on His Induction Into the NJ League of Municipalities Hall of Fame



WARREN, N.J., Dec. 05, 2024 (GLOBE NEWSWIRE) -- , CEO of (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: ), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, congratulates Board Member, PE, CSP, MBA, as he was inducted into The New Jersey League of Municipalities Hall of Fame this month.

Mayor Sordillo was inducted into the Hall of Fame for his dedicated tenure of 24 years of continuous service as a Warren Township Committee Member. As an elected official, Mayor Sordillo served the community by leading the municipal government, providing oversight to the township’s operations, and implementing policies for the public good, essentially working for the benefit of the citizens he represents.

“Mayor Sordillo exemplifies the qualities of a dedicated public servant, making personal sacrifices to answer a call that many shy away from. While policy debates are essential and differing perspectives form the bedrock of democracy, such discussions are incomplete without acknowledging the personal commitments and sacrifices made by leaders like Mayor Sordillo. We extend our deepest gratitude and congratulations on your remarkable service.” said Ryan Saadi, MD, MPH, Tevogen Bio’s Chief Executive Officer.

“It has been an honor to serve the residents of Warren and be part of a very high performing team of committee people. During our tenure, we built a new library, a new town hall, extensive youth facilities including the football complex, playgrounds, and basketball courts; and purchased around 1,000 acres of open space which includes the Wagner Farm. This was accomplished while maintaining a AAA bond rating and having one tenth of the long-term debt allowable by the State of NJ.” said Mayor Sordillo.

Former New Jersey Governor Don DeFrancesco and current State Senator John Bramnick recognized Warren Township and its leadership, both having said that the Township is a model for the State and one of the best places to live. During the Mayor’s term, Warren was voted by Money magazine as the sixth best place to live in America; and again by New Jersey Monthly, as the second-best place to live in Central NJ.

Mayor Sordillo will be honored along with Gary DiNardo, Carolann Garafola, and the late Frank Salvato during an event next week.

About Tevogen Bio

Tevogen is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence.

Tevogen is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen’s leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation.

Contacts

Tevogen Bio Communications

T: 1 877 TEVOGEN, Ext 701

 

A photo accompanying this announcement is available at



EN
05/12/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on TEVOGEN BIO HOLDINGS INC

 PRESS RELEASE

Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Pr...

Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships WARREN, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today provided stockholders with a detailed overview of its artificial intelligence initiative, Tevogen.AI™. Tevogen.AI™ aims to integrate advanced machine learning and predictive modeling into Tevogen Bio’s proprietary ExacTcell™ technology to significantly enhance its target identification and pre-clinical processes, thereby strengthening ...

 PRESS RELEASE

Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patient...

Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year; Updated rNPV to Follow WARREN, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today announced a planned expansion of TVGN 489’s target population to include patients 65 and older. , the top-line revenue forecast for the specialty care pipeline was projected at nearly $1 billion in its launch year, with a cumulative five-year estimate ranging between $18 billion and $22 billion. This anticipated expan...

 PRESS RELEASE

Tevogen to Update on Robust Portfolio Assets, Business Expansion, Part...

Tevogen to Update on Robust Portfolio Assets, Business Expansion, Partnerships, Limited Tradable Float, High Insider Ownership and Strong Investor Confidence Ahead of June 23 Annual Meeting WARREN, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today announced that it will provide several updates to stockholders in advance of the Company’s upcoming Annual Meeting of Stockholders scheduled for June 23, 2025. These updates will provide content regarding the Company’s innovative business model and strategic growth initiatives, which management ...

 PRESS RELEASE

Tevogen Bio's Business Model Addresses Biopharma Industry Challenges w...

Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation WARREN, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ). As the biopharma industry faces increasing competition from international markets and an evolving regulatory landscape, Tevogen Bio’s innovative business model positions it as a potential leader in the shift towards cost-efficient, value-driven healthcare. With the concern of Chinese pharmaceutical companies developing drugs at a faster pace and lower cost, the U.S. biotech sector faces p...

 PRESS RELEASE

Tevogen to Share Direct Registration System (DRS) Process Details Foll...

Tevogen to Share Direct Registration System (DRS) Process Details Following Increased Shareholder Interest WARREN, N.J., May 02, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ) today announced that, following the Company’s recent press release highlighting the Direct Registration System (DRS) as a secure method of share ownership, it has received a number of inquiries from shareholders seeking additional information on how to transfer their shares to a DRS account. In response, Tevogen will provide step-by-step guidance early next week to help interested s...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch